RSV
Long-term clinical trial engagement is a behavioural challenge – not just an informational one
Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.
Study shows infants given RSV vaccination benefit beyond first RSV season
The RSV virus is highly contagious and can cause serious respiratory illness for infants
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition
The deal includes an early-stage combination vaccine candidate for RSV and hMPV
Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults
The vaccine is already approved in the US for use in adults aged 60 years and older
Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants
Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight
Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years
Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group
Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults
RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older
UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance
The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year
GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
The respiratory virus is estimated to impact 64 million people globally every year
GSK’s RSV vaccine Arexvy approved by EC for use in adults aged 50 to 59 years
An estimated 20 million adults in this age population are at an increased risk of severe RSV outcomes
Pfizer shares promising phase 3 results for RSV vaccine in immunocompromised adults
There are currently no RSV vaccines approved for adults aged 18 to 59 years in the US